CytoLumina Technologies Corp. is dedicated to expanding precision medicine through the development of nanotechnology-enabled rare-cell capture and sorting platforms. The company is focused on making dramatic improvements in patient quality of life by developing assays that capture rare circulating tumor cells (CTCs) from a standard blood sample. With over a decade of research and development of liquid biopsy techniques for solid tumors, the Cytolumina CytoTrapNano™ (also known as NanoVelcro chip in the scientific literature) enables high-frequency monitoring of disease progression, resulting in more confident and effective treatment decisions. CytoLumina Technologies Corp. is a pioneer among companies developing CTC capture technologies.
Cytolumina Joins Cancer Moonshot’s Blood Profiling Atlas to advance circulating tumor cell research.